The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) is a huge mover today! About 314,867 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 11.83% since April 4, 2016 and is uptrending. It has outperformed by 10.74% the S&P500.
The move comes after 8 months positive chart setup for the $1.39 billion company. It was reported on Nov, 4 by Barchart.com. We have $65.08 PT which if reached, will make NASDAQ:FPRX worth $472.60M more.
Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage
Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Citigroup initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Tuesday, October 25 with “Buy” rating. The firm earned “Outperform” rating on Friday, March 11 by Credit Suisse. The firm has “Sell” rating given on Tuesday, August 11 by Zacks. As per Friday, December 4, the company rating was maintained by Wells Fargo. Citigroup initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Friday, July 31 with “Buy” rating. The rating was initiated by Credit Suisse with “Outperform” on Thursday, January 21. The firm has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets. As per Friday, August 21, the company rating was upgraded by Zacks. Oppenheimer maintained it with “Outperform” rating and $48 target price in Monday, October 19 report.
According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 2.29 in 2016 Q2. Its up 1.04, from 1.25 in 2016Q1. The ratio is positive, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.
Bogle Investment Mgmt Limited Partnership De accumulated 328,329 shares or 0.94% of the stock. Fifth Third Fincl Bank accumulated 0% or 300 shares. Great West Life Assurance Communication Can accumulated 0% or 2,346 shares. Moreover, D E Shaw Com Inc has 0.01% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 72,199 shares. Convergence Inv Partners Limited Liability Corporation holds 0.12% or 20,480 shares in its portfolio. Moreover, Aqr Capital Mgmt Ltd Com has 0.01% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 120,122 shares. Awm Invest has invested 0.8% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Gru has invested 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Canada Pension Plan Board has invested 0.08% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Virginia Retirement Et Al reported 26,500 shares or 0.02% of all its holdings. Rs Invest Management Llc accumulated 539,193 shares or 0.23% of the stock. Assetmark holds 18 shares or 0% of its portfolio. Spot Trading Llc last reported 600 shares in the company. Tudor Investment Corp Et Al has 0.01% invested in the company for 12,300 shares. California State Teachers Retirement Sys has 0.01% invested in the company for 56,575 shares.
Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 5 sales for $701,473 net activity. RINGO WILLIAM R sold 500 shares worth $24,335. $603,653 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) was sold by Jensen Peder.
More notable recent Five Prime Therapeutics Inc (NASDAQ:FPRX) news were published by: Streetinsider.com which released: “Form RW FIVE PRIME THERAPEUTICS” on November 03, 2016, also Benzinga.com with their article: “Citi Launches Positive Coverage On Five Prime Therapeutics” published on October 25, 2016, Nasdaq.com published: “Commit To Buy Five Prime Therapeutics At $40, Earn 13.4% Annualized Using Options” on November 01, 2016. More interesting news about Five Prime Therapeutics Inc (NASDAQ:FPRX) were released by: Reuters.com and their article: “BRIEF-Five Prime Therapeutics says Aron Knickerbocker promoted to COO” published on September 20, 2016 as well as Globenewswire.com‘s news article titled: “Five Prime Therapeutics to Announce Third Quarter 2016 Financial Results and …” with publication date: October 20, 2016.
FPRX Company Profile
Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.